Apixaban Formulations

Patent No. EP3017811 (titled "Apixaban Formulations") was filed by Bristol Myers Squibb on Feb 24, 2011. The application was issued on Dec 5, 2018.

Patent Summary

Tablets containing apixaban for treating thromboembolic disorders with improved bioavailability by using apixaban particles with a maximum size cutoff of less than 89 microns. The tablets are made by a dry granulation process that produces apixaban particles with a d90 size below 89 microns. This allows consistent in vivo dissolution and exposure compared to larger particles. The smaller particle size improves absorption and therapeutic efficacy compared to tablets with larger particles made by wet granulation or using large apixaban particles.

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3017811

BRISTOL MYERS SQUIBB
Application Number
EP15190823A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Publication Date
Dec 5, 2018